Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21977e40c08969f3e950eb43ecafe0cb |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-557 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00 |
filingDate |
1991-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
1993-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6405748d058dd54789f34da6e07dc40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bc0febae22ff26918f64bd3236f713d |
publicationDate |
1993-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-5212200-A |
titleOfInvention |
Ocular hypotensive agents |
abstract |
The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8686035-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004225014-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003060511-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6770675-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02092098-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008033036-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005014837-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03018025-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003220396-A1 |
priorityDate |
1987-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |